Stanley C Jordan1, Tomas Lorant1, Jua Choi1, Christian Kjellman1, Lena Winstedt1, Mats Bengtsson1, Xiaohai Zhang1, Torsten Eich1, Mieko Toyoda1, Britt-Marie Eriksson1, Shili Ge1, Alice Peng1, Sofia Järnum1, Kathryn J Wood1, Torbjorn Lundgren1, Lars Wennberg1, Lars Bäckman1, Erik Larsson1, Rafael Villicana1, Joe Kahwaji1, Sabrina Louie1, Alexis Kang1, Mark Haas1, Cynthia Nast1, Ashley Vo1, Gunnar Tufveson1. 1. From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology (M.H., C.N.), Cedars-Sinai Medical Center, Los Angeles; the Section of Transplantation Surgery, Department of Surgical Sciences (T. Lorant, L.B., G.T.), the Section of Molecular and Morphological Pathology (M.B., E.L.) and the Section of Clinical Immunology (T.E.), Department of Immunology, Genetics, and Pathology, and the Section of Infectious Diseases, Department of Medical Sciences (B.-M.E.), Uppsala University, Uppsala, Hansa Medical, Lund (C.K., L. Winstedt, S.J.), and the Division of Transplantation Surgery, Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, and the Department of Transplantation Surgery, Karolinska University Hospital, Stockholm (T. Lundgren, L. Wennberg) - all in Sweden; and the Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom (K.J.W.).
Abstract
BACKGROUND: Donor-specific antibodies create an immunologic barrier to transplantation. Current therapies to modify donor-specific antibodies are limited and ineffective in the most highly HLA-sensitized patients. The IgG-degrading enzyme derived from Streptococcus pyogenes (IdeS), an endopeptidase, cleaves human IgG into F(ab')2 and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be useful for desensitization. We report on the combined experience of two independently performed open-label, phase 1-2 trials (conducted in Sweden and the United States) that assessed the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor. METHODS: We administered IdeS to 25 highly HLA-sensitized patients (11 patients in Uppsala or Stockholm, Sweden, and 14 in Los Angeles) before the transplantation of a kidney from an HLA-incompatible donor. Frequent monitoring for adverse events, outcomes, donor-specific antibodies, and renal function was performed, as were renal biopsies. Immunosuppression after transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids. Patients in the U.S. study also received intravenous immune globulin and rituximab after transplantation to prevent antibody rebound. RESULTS: Recipients in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement of the organ and transplantation), a significantly higher rate of delayed graft function, and significantly higher levels of class I donor-specific antibodies than those in the Swedish study. A total of 38 serious adverse events occurred in 15 patients (5 events were adjudicated as being possibly related to IdeS). At transplantation, total IgG and HLA antibodies were eliminated. A total of 24 of 25 patients had perfusion of allografts after transplantation. Antibody-mediated rejection occurred in 10 patients (7 patients in the U.S. study and 3 in the Swedish study) at 2 weeks to 5 months after transplantation; all these patients had a response to treatment. One graft loss, mediated by non-HLA IgM and IgA antibodies, occurred. CONCLUSIONS: IdeS reduced or eliminated donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of 25 patients. (Funded by Hansa Medical; ClinicalTrials.gov numbers, NCT02224820 , NCT02426684 , and NCT02475551 .).
BACKGROUND:Donor-specific antibodies create an immunologic barrier to transplantation. Current therapies to modify donor-specific antibodies are limited and ineffective in the most highly HLA-sensitized patients. The IgG-degrading enzyme derived from Streptococcus pyogenes (IdeS), an endopeptidase, cleaves human IgG into F(ab')2 and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be useful for desensitization. We report on the combined experience of two independently performed open-label, phase 1-2 trials (conducted in Sweden and the United States) that assessed the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor. METHODS: We administered IdeS to 25 highly HLA-sensitized patients (11 patients in Uppsala or Stockholm, Sweden, and 14 in Los Angeles) before the transplantation of a kidney from an HLA-incompatible donor. Frequent monitoring for adverse events, outcomes, donor-specific antibodies, and renal function was performed, as were renal biopsies. Immunosuppression after transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids. Patients in the U.S. study also received intravenous immune globulin and rituximab after transplantation to prevent antibody rebound. RESULTS: Recipients in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement of the organ and transplantation), a significantly higher rate of delayed graft function, and significantly higher levels of class I donor-specific antibodies than those in the Swedish study. A total of 38 serious adverse events occurred in 15 patients (5 events were adjudicated as being possibly related to IdeS). At transplantation, total IgG and HLA antibodies were eliminated. A total of 24 of 25 patients had perfusion of allografts after transplantation. Antibody-mediated rejection occurred in 10 patients (7 patients in the U.S. study and 3 in the Swedish study) at 2 weeks to 5 months after transplantation; all these patients had a response to treatment. One graft loss, mediated by non-HLA IgM and IgA antibodies, occurred. CONCLUSIONS:IdeS reduced or eliminated donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of 25 patients. (Funded by Hansa Medical; ClinicalTrials.gov numbers, NCT02224820 , NCT02426684 , and NCT02475551 .).
Authors: Jean Kwun; Marie Matignon; Miriam Manook; Soulef Guendouz; Vincent Audard; David Kheav; Elsa Poullot; Chantal Gautreau; Brian Ezekian; Diane Bodez; Thibault Damy; Laureline Faivre; Dehbia Menouch; Janghoon Yoon; Jaeberm Park; Karim Belhadj; Dongfeng Chen; Alyssa M Bilewski; John S Yi; Bradley Collins; Mark Stegall; Alton B Farris; Stuart Knechtle; Philippe Grimbert Journal: J Am Soc Nephrol Date: 2019-06-21 Impact factor: 10.121
Authors: Ronald F Parsons; Arslan Zahid; Shalini Bumb; Hannah Decker; Harold C Sullivan; Frances Eun-Hyung Lee; Idelberto Raul Badell; Mandy L Ford; Christian P Larsen; Thomas C Pearson; Annette M Jackson; Dong-Feng Chen; Matthew Levine; Malek Kamoun; Robert A Bray; Howard M Gebel Journal: Am J Transplant Date: 2019-10-08 Impact factor: 8.086